Adam Koppel - Partner of Bain Capital Life Sciences Investors, LLC
Location
Boston, MA
Holdings as of
December 31, 2020
Value $
$1.59B
Num holdings
26
Date filed
2/16/2021, 06:13 AM
Description
All US holdings of this investor are reported in this report. The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as
of the end of the calendar quarter for which the report is filed, and the total market value. The market value
column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in
accounts.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Adam Koppel
Managing Dir. of Bain Capital Life Sciences Investors, LLC
Boston, Massachusetts
2/16/2021
Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP and (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P. The shares of common stock of Dynavax Technologies Corporation ("DVAX") included on the Information Table are as reported on Amendment No. 2 to the Schedule 13D filed by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP on May 28, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of DVAX common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding DVAX common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 8,525,000 shares of DVAX common stock.The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 30, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 4,571,139 shares of SVRA common stock.The shares of common stock of X4 Pharmaceuticals, Inc. ("XFOR") included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 9, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of XFOR common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding XFOR common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 1,250,000 shares of XFOR common stock. The shares of common stock of Syros Pharmaceuticals, Inc. ("SYRS" ) included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 14, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SYRS common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SYRS common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 4,000,000 shares of SYRS common stock.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.